2 results
Approved WMORecruiting
To demonstrate safety and efficacy of Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DESin wide clinical use.
Approved WMOCompleted
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…